Showing 871-880 of 3410 results for "".
Lose Your Inhibitions: Expanding Use of JAK Inhibitors
https://practicaldermatology.com/topics/atopic-dermatitis/lose-your-inhibitions-expanding-use-of-jak-inhibitors/23910/Despite data on safety concerns, dermatologists and patients see benefits.Women in Dermatology: Iris Rubin, MD
https://practicaldermatology.com/topics/practice-management/women-in-dermatology-iris-rubin-md/23589/A Leg Up: Neuromuscular Electrical Stimulation of the Quadriceps
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-leg-up-neuromuscular-electrical-stimulation-of-the-quadriceps/23389/Patients report functional gains associated with treatment.Biosimilars: Generic Biologics or Something Much More Complex?
https://practicaldermatology.com/topics/practice-management/biosimilars-generic-biologics-or-something-much-more-complex/21013/The looming availability of biosimilar medications raises important clinical and regulatory questions.Maui Derm 2024 and Maui Derm Caribbean: Top Stories, Interviews, and More
https://practicaldermatology.com/conferences/maui-derm-2024/maui-derm-2024-and-maui-derm-caribbean-top-stories-interviews-and-more/24043/The sun was bright, and the science was hot at Maui Derm 2024, held at the Grand Wailea Resort in Maui, Hawaii. From new therapies to innovative techniques to treatments in the pipeline, presenters and attendees were eager to share updates and findings at this popular annual event.The Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobDEI in Dermatology
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/dei-in-dermatology/20143/Dermatology remains one of the least diverse medical specialties, says Jeanine Downie, MD. There have been small steps forward to improve diversity, equity, inclusion, and accessibility in recent years, such as the DREAM initiative from Allergan Aesthetics and skinbetter science. But there is stillNailed It: Foods for Hair and Nails
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nailed-it-foods-for-hair-and-nails/19932/Zoe Draelos, MD is nuts about natural sources of nutrition and has some berry good news for those interested in alternative to supplements for the hair and nails. Hint: Not everyone needs supplements, she says.The Male Aesthetic Patient: Who He Is and What He Needs
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-male-aesthetic-patient-who-he-is-and-what-he-needs/18701/Baby boomer men aren't necessarily driving the growth in male aesthetics. Terrence Keaney, MD says that millennial men in their 30s and 40s are most likely to seek treatments. In the initial consultation, education is essential so men understand the treatments offered and recognize that you understa